|
|
Champions Oncology Inc (NASDAQ: CSBR) |
|
Price: $6.2700
$-0.19 
-2.941%
|
| Day's High:
| $6.54
| Week Perf:
| -1.72 %
|
| Day's Low: |
$ 6.27 |
30 Day Perf: |
0.8 % |
| Volume (M): |
11 |
52 Wk High: |
$ 11.99 |
| Volume (M$): |
$ 66 |
52 Wk Avg: |
$6.59 |
| Open: |
$6.54 |
52 Wk Low: |
$3.60 |
|
|
| Market Capitalization (Millions $) |
90 |
| Shares
Outstanding (Millions) |
14 |
| Employees |
160 |
| Revenues (TTM) (Millions $) |
59 |
| Net Income (TTM) (Millions $) |
6 |
| Cash Flow (TTM) (Millions $) |
-1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Champions Oncology Inc
Champions Oncology Inc is a biotechnology company that specializes in developing and providing personalized medicine solutions for cancer patients. The company offers services that include creating patient-derived tumor xenograft (PDX) models, which are used for drug testing and development. These PDX models are derived directly from patients' tumors and aim to replicate the complexity and diversity of the original tumor biology, allowing for more accurate and personalized treatment approaches. Champions Oncology's services also include biomarker analysis, genetic profiling, and drug sensitivity testing. The company collaborates with pharmaceutical and biotechnology companies to advance the development of new cancer therapies.
Company Address: One University Plaza, Suite 307 Hackensack 7601 NJ
Company Phone Number: 808-8400 Stock Exchange / Ticker: NASDAQ CSBR
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Champions Oncology Inc
Champions Oncology Inc: Year-to-Date Performance AnalysisIn an analysis of Champions Oncology Inc's market performance this year, it appears that the company's shares have increased by 19.34%. However, this figure falls short compared to the broader market, which has enjoyed a robust 24.43% performance over the same period. This divergence raises questions about the factors influencing Champions Oncology's stock performance and its underlying business fundamentals, especially in light of its recent financial results. Financial Performance InsightsFor the second quarter of 2025, Champions Oncology reported its first positive earnings per share (EPS) of $0.05, a notable turnaround from a loss of $-0.15 per share a year ago. While this signifies improvement, it is crucial to note that this number represents a drop of 44.44% from the prior reporting period, where the company achieved an EPS of $0.09. Despite this volatility in earnings, the revenue figures tell a more encouraging story.
|
| Champions Oncology Inc
Champions Oncology Inc. is a company that specializes in providing personalized medicine solutions for cancer patients. They offer a unique platform called TumorGraft, which enables oncologists to test and develop treatment plans based on the individual characteristics of a patient's tumor. This approach helps to improve the efficacy and success rate of cancer treatment.
In terms of the company's financial performance, the November to January 31, 2024 financial period showed an increased deficit per share of $-0.19 compared to $-0.18 the previous year. There was also an increased deficit from $-0.15 per share from the prior reporting season. This indicates that the company's expenses exceeded its revenues during this period.
|
| Champions Oncology Inc
Champions Oncology Inc, a leading company in the field of personalized medicine, has experienced a drop in its stock price over the past five trading days. The stock has declined by -6.23%, bringing its year-to-date performance to 12.44%. Additionally, the stock is currently trading only 32.5% above its 52-week low.
One factor that may have contributed to the recent decline in the stock price is the company's financial performance in the fiscal second quarter of 2024. During this period, Champions Oncology Inc reported a widening of losses, with a loss of $-0.15 per share compared to zero earnings per share in the same period the previous year. However, there was an improvement in earnings per share from the prior quarter, with a decrease to $-0.19 per share.
|
| Champions Oncology Inc
Champions Oncology Inc, a company listed on the NASDAQ, has experienced some fluctuations in its stock performance recently. In the preceding month, the stock declined by -3.59%, indicating a slight decrease in investor confidence. However, when considering the overall trend, the stock is still showing a significant increase of 52.04% in 2023.
Currently, Champions Oncology Inc's stock is trading on the NASDAQ at a level that is 15.3% above its 52-week average. This suggests that investors have generally been optimistic about the company's prospects, as the stock is trading at a higher price than what has been seen over the past year.
However, the company's financial performance in the first quarter of 2024 has been less than desirable. Lower turnover has resulted in dwindling revenue, which has further exacerbated an increased shortfall. The company experienced a net shortfall of $-0.19 per share, a significant decline compared to the previous reporting period where the bottom line was also $-0.19 per share.
|
| Champions Oncology Inc
Champions Oncology Inc, a biotechnology and pharmaceutical company, has seen significant improvement in its shares over the past month. The stock price has surged by 19.86% during this period, and over the course of 2023, it has increased by an impressive 49.56%. Currently trading on the NASDAQ, the company's shares are 8.6% above its 52-week average.
However, despite the positive performance of the company's shares, the financial data for the period of February to April 2023 reveals some challenges. Champions Oncology Inc experienced a loss per share of $-0.19, compared to $-0.02 in the previous year. Additionally, the net loss increased from $-0.18 per share in the previous quarter. These figures indicate a decline in profitability for the company.
|
| Per Share |
Current |
| Earnings (TTM) |
0.44 $ |
| Revenues (TTM) |
4.08 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.22 $
|
| Book Value |
0.38 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
0.44 $
|
| Revenues (TTM) |
4.08 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.22 $
|
| Book Value |
0.38 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Pharmacology services |
|
 68.49 % |
of total Revenue |
| TOS license revenue |
|
26.41 % |
of total Revenue |
| Other TOS revenue |
|
5.1 % |
of total Revenue |
|
|
